When is CAR T-cell therapy recommended for acute lymphoblastic leukaemia?

CAR T-cell therapy uses a person’s own T cells, which are collected and changed in a laboratory so they can recognise a marker on leukaemia cells. The cells are returned after a preparation treatment. Eligibility depends on the type of ALL, the marker found on the leukaemia cells, previous therapies, disease activity, age, organ function and ability to manage intensive monitoring.

The treatment can cause serious immune reactions, changes in blood counts and effects on the nervous system. A specialist team explains these issues and the need to remain close to the treatment centre during the monitoring period.

Ask the haematology team whether testing has confirmed the relevant cell marker and whether CAR T-cell therapy is suitable at this point. Discuss other treatment choices, the cell-collection process, preparation treatment, hospital stay, fertility concerns, infection precautions and the practical need for a caregiver. Bring a complete list of medicines and tell the team about recent infections or neurological symptoms.

During or after treatment, urgently report fever, chills, dizziness, confusion, severe headache, difficulty speaking, seizure, unusual sleepiness, breathing difficulty or fainting. These can signal complications that need rapid assessment. Follow the centre’s instructions about temperature checks and emergency contact, including when travelling home after treatment.

Ask why CAR T-cell therapy is being considered now, what testing is still needed, how long cell preparation may take, what monitoring is required, and which symptoms mean you should call immediately. Clarify the plan if the therapy cannot be given or does not control the leukaemia.